Conventional surgery results in patients originally referred for transcatheter aortic valve implantation
Authors:
- Tommaso PivaTPTommaso Piva
- Ilaria MazzantiIMIlaria Mazzanti
- Carlo AratariCACarlo Aratari
- Giuseppe PupitaGPGiuseppe Pupita
- Sacha MatteucciSMSacha Matteucci
- Alessandro D’alfonsoADAlessandro D’alfonso
- Alessandro CapucciACAlessandro Capucci
- Gian Piero PernaGPGian Piero Perna
- Lucia TorraccaLTLucia Torracca
Open Access
- 1 April 2015
- journal article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 16 (4) , 267-270
Abstract
Aims Transcatheter aortic valve implantation (TAVI) is increasingly considered as a viable alternative to conventional aortic valve replacement (AVR) in high-risk patients. Long-term results, however, are still scarce and medical community hesitates in enlarging indications to lower-risk patients. Moreover, available devices are expensive and a strict potential candidate selection is necessary. Methods From April 2008 to August 2012, a total of 212 patients, originally referred for percutaneous treatment, were thoroughly evaluated by the aortic team of our department in order to choose the optimal procedure. Of them, 55 patients (35 women; 20 men) were considered as still acceptable candidates for conventional AVR. Results Mean age was 80.7 ± 4.7 years; mean additive and logistic Euroscore I were 9.7 ± 1.8 and 17.8 ± 9.5%, respectively. Mean Euroscore II was 7.9 ± 5.5%. Mean New York Heart Association class was 2.9 ± 0.5. The majority of patients (87.2%) presented a geriatric frailty score of 0–1. Four patients showed a heavily calcified ascending aorta, and five patients (9%) underwent reoperations. Hospital mortality was 10.9% (six patients). Mean follow-up was 535.9 ± 407.4 days (range: 6–1365 days). Six other patients died during this period for a mean survival of 74.4 ± 6.9% at 2 years. Mean New York Heart Association class at 1 year was 1.25 ± 0.5 (P < 0.01 vs. preoperative value). Conclusion AVR should be indicated with caution in high-risk patients originally referred for TAVI. Despite medium-term results being good, with excellent functional status, hospital mortality is not negligible.Keywords
This publication has 18 references indexed in Scilit:
- The SURTAVI model: proposal for a pragmatic risk stratification for patients with severe aortic stenosisEuroIntervention, 2012
- A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable populationBMJ Open, 2012
- Registry of Transcatheter Aortic-Valve Implantation in High-Risk PatientsNew England Journal of Medicine, 2012
- Clinical Outcomes of Patients With Severe Aortic Stenosis at Increased Surgical Risk According to Treatment ModalityJACC, 2011
- Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk PatientsNew England Journal of Medicine, 2011
- Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo SurgeryNew England Journal of Medicine, 2010
- Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: Changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National DatabaseThe Journal of Thoracic and Cardiovascular Surgery, 2009
- Burden of valvular heart diseases: a population-based studyThe Lancet, 2006
- A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart DiseaseEuropean Heart Journal, 2003
- A brief clinical instrument to classify frailty in elderly peopleThe Lancet, 1999